tradingkey.logo

Merck announces phase 3 hyperion study of Winrevair

ReutersJun 23, 2025 10:47 AM

- Merck & Co Inc MRK.N:

  • MERCK ANNOUNCES PHASE 3 HYPERION STUDY OF WINREVAIR™ (SOTATERCEPT-CSRK) MET PRIMARY ENDPOINT IN RECENTLY DIAGNOSED ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)

  • MERCK & CO INC - WINREVAIR REDUCED RISK OF CLINICAL WORSENING EVENTS IN PAH PATIENTS

  • MERCK & CO INC - HYPERION MET PRIMARY ENDPOINT OF TIME TO CLINICAL WORSENING

  • MERCK & CO INC - WINREVAIR SAFETY PROFILE CONSISTENT WITH PREVIOUS STUDIES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI